TEAM (TrEatment Approach in the Multimodal Era) Registry
The TEAM Registry is designed as a prospective, observational, multicentre, multinational registry to investigate the longitudinal management of newly-referred CTEPH patients at expert centres offering all three currently available treatment modalities to patients, i.e. PEA surgery, BPA and medical treatment. Patient enrolment is scheduled to start in Q3 2022 and will continue for 24 months or until reaching 1000 participants. Registry closure is expected in Q3 2027, after a 3-year follow-up period.
The main objectives of the registry are to:
- Document the multimodality approach to CTEPH
- Measure outcomes in terms of survival and post-treatment experience
- Record complication rates of interventional treatments (PEA and BPA)
- Document vital status at 1, 3 and 5 years
The TEAM Registry will involve approximately 30 expert centres around the globe. Site selection is currently ongoing; sites are selected based on the routine use of all available treatment modalities.
The registry is set up as a collaborative study between the ICA and Janssen Pharmaceuticals, who are providing financial support.